Performance of Relative Exchangeable Copper for the Diagnosis of Wilson Disease in Acute Liver Failure
- PMID: 40097333
- PMCID: PMC11913634
- DOI: 10.1002/jimd.70024
Performance of Relative Exchangeable Copper for the Diagnosis of Wilson Disease in Acute Liver Failure
Abstract
Acute liver failure (ALF) can be one of the manifestations of Wilson disease (WD), and due to its severity, prompt diagnosis is essential. A ratio > 15% of the exchangeable copper to total serum copper, known as relative exchangeable copper (REC), has been shown to have a 100% sensitivity and specificity for the diagnosis of WD but this has not yet been studied in an ALF setting. Patients diagnosed with ALF from 1 November 2011 to 31 December 2023, with available REC determination during the acute event, were included. Thirty-three patients were included (11 with WD and 22 without WD). The median age [IQR] at ALF was 12.9 [8.9-20.2] years, range: 0.6-71.0 years. Serum ceruloplasmin (Cp) < 0.20 g/L and 24 h urinary copper excretion > 1.6 μmol/L had both a sensitivity (Se) and specificity (Sp) for the diagnosis of WD of 100% and 72.7%, respectively. A ROC analysis of REC determined that the best cut-off point was 14.4% (AUC 1, p < 0.01). All the WD patients had REC values > 14.4%, yielding a sensitivity and specificity of 100. Relative exchangeable copper has 100% sensitivity and specificity for diagnosing Wilson disease in acute liver failure. Relative exchangeable copper has excellent performance in diagnosing Wilson disease in acute liver failure.
Keywords: Wilson disease; acute liver failure; ceruloplasmin; exchangeable copper; relative exchangeable copper; urinary copper.
© 2025 The Author(s). Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Conflict of interest statement
Eduardo Couchonnal received consulting fees, honoraria for presentations, or support to attend meetings from ORPHALAN, UNIVAR, ALEXION, and VIVET THERAPEUTICS. Olivier Guillaud received consulting fees, honoraria for presentations, or support to attend meetings from ORPHALAN, ABBVIE, GILEAD, AMGEN. Daniela Spirea1, Claire Vanlemmens, François Parant, Teresa Antonini5, Muriel Bost, Alain Lachaux, Abdelouahed Belmalih, and Jerome Dumortier declare that they have no conflicts of interest.
Figures
References
-
- Guillaud O., Brunet A.‐S., Mallet I., et al., “Relative Exchangeable Copper: A Valuable Tool for the Diagnosis of Wilson Disease,” Liver International 38 (2018): 350–357. - PubMed
-
- Schilsky M. L., Roberts E. A., Bronstein J. M., et al., “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance on Wilson Disease From the American Association for the Study of Liver Diseases,” Hepatology 77, no. 4 (2023): 1–49, 10.1002/hep.32801. - DOI - PubMed
-
- Socha P., Janczyk W., Dhawan A., et al., “Wilson's Disease in Children: A Position Paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition,” Journal of Pediatric Gastroenterology and Nutrition 66, no. 2 (2018): 334–344, 10.1097/MPG.0000000000001787. - DOI - PubMed
-
- Vandriel S. M., Ayoub M. D., Ricciuto A., et al., “Pediatric Wilson Disease Presenting as Acute Liver Failure: An Individual Patient Data Meta‐Analysis,” Journal of Pediatric Gastroenterology and Nutrition 71 (2020): e90–e96. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical